93 related articles for article (PubMed ID: 11696598)
1. B7H costimulates clonal expansion of, and cognate destruction of tumor cells by, CD8(+) T lymphocytes in vivo.
Liu X; Bai XF; Wen J; Gao JX; Liu J; Lu P; Wang Y; Zheng P; Liu Y
J Exp Med; 2001 Nov; 194(9):1339-48. PubMed ID: 11696598
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxic T lymphocytes form an antigen-independent ring junction.
Somersalo K; Anikeeva N; Sims TN; Thomas VK; Strong RK; Spies T; Lebedeva T; Sykulev Y; Dustin ML
J Clin Invest; 2004 Jan; 113(1):49-57. PubMed ID: 14702108
[TBL] [Abstract][Full Text] [Related]
3. CD206+ tumor-associated macrophages cross-present tumor antigen and drive antitumor immunity.
Modak M; Mattes AK; Reiss D; Skronska-Wasek W; Langlois R; Sabarth N; Konopitzky R; Ramirez F; Lehr K; Mayr T; Kind D; Viollet C; Swee LK; Petschenka J; El Kasmi KC; Noessner E; Kitt K; Pflanz S
JCI Insight; 2022 Jun; 7(11):. PubMed ID: 35503656
[TBL] [Abstract][Full Text] [Related]
4. Engagement of the costimulatory molecule ICOS in tissues promotes establishment of CD8
Peng C; Huggins MA; Wanhainen KM; Knutson TP; Lu H; Georgiev H; Mittelsteadt KL; Jarjour NN; Wang H; Hogquist KA; Campbell DJ; Borges da Silva H; Jameson SC
Immunity; 2022 Jan; 55(1):98-114.e5. PubMed ID: 34932944
[TBL] [Abstract][Full Text] [Related]
5. Plasma IL-8 and ICOSLG as prognostic biomarkers in glioblastoma.
Holst CB; Christensen IJ; Vitting-Seerup K; Skjøth-Rasmussen J; Hamerlik P; Poulsen HS; Johansen JS
Neurooncol Adv; 2021; 3(1):vdab072. PubMed ID: 34286278
[TBL] [Abstract][Full Text] [Related]
6. Combination Therapy of Novel Oncolytic Adenovirus with Anti-PD1 Resulted in Enhanced Anti-Cancer Effect in Syngeneic Immunocompetent Melanoma Mouse Model.
Garofalo M; Bertinato L; Staniszewska M; Wieczorek M; Salmaso S; Schrom S; Rinner B; Pancer KW; Kuryk L
Pharmaceutics; 2021 Apr; 13(4):. PubMed ID: 33919827
[TBL] [Abstract][Full Text] [Related]
7. Balancing Inflammation and Central Nervous System Homeostasis: T Cell Receptor Signaling in Antiviral Brain T
Netherby-Winslow CS; Ayers KN; Lukacher AE
Front Immunol; 2020; 11():624144. PubMed ID: 33584727
[TBL] [Abstract][Full Text] [Related]
8. The ICOSL Expression Predicts Better Prognosis for Nasopharyngeal Carcinoma via Enhancing Oncoimmunity.
Zhang G; Xu Y; Zhang S; Zhou H
Biomed Res Int; 2020; 2020():9756732. PubMed ID: 31998801
[TBL] [Abstract][Full Text] [Related]
9. T-cell co-stimulation in combination with targeting FAK drives enhanced anti-tumor immunity.
Canel M; Taggart D; Sims AH; Lonergan DW; Waizenegger IC; Serrels A
Elife; 2020 Jan; 9():. PubMed ID: 31959281
[TBL] [Abstract][Full Text] [Related]
10. ICOSLG-mediated regulatory T-cell expansion and IL-10 production promote progression of glioblastoma.
Iwata R; Hyoung Lee J; Hayashi M; Dianzani U; Ofune K; Maruyama M; Oe S; Ito T; Hashiba T; Yoshimura K; Nonaka M; Nakano Y; Norian L; Nakano I; Asai A
Neuro Oncol; 2020 Mar; 22(3):333-344. PubMed ID: 31634400
[TBL] [Abstract][Full Text] [Related]
11. Expression of ICOSL is associated with decreased survival in invasive breast cancer.
Wang B; Jiang H; Zhou T; Ma N; Liu W; Wang Y; Zuo L
PeerJ; 2019; 7():e6903. PubMed ID: 31143539
[TBL] [Abstract][Full Text] [Related]
12. Inducible Costimulator Expressing T Cells Promote Parasitic Growth During Blood Stage
Jogdand GM; Sengupta S; Bhattacharya G; Singh SK; Barik PK; Devadas S
Front Immunol; 2018; 9():1041. PubMed ID: 29892278
[TBL] [Abstract][Full Text] [Related]
13. A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.
Du X; Tang F; Liu M; Su J; Zhang Y; Wu W; Devenport M; Lazarski CA; Zhang P; Wang X; Ye P; Wang C; Hwang E; Zhu T; Xu T; Zheng P; Liu Y
Cell Res; 2018 Apr; 28(4):416-432. PubMed ID: 29472691
[TBL] [Abstract][Full Text] [Related]
14. Attenuation of immune-mediated influenza pneumonia by targeting the inducible co-stimulator (ICOS) molecule on T cells.
Sakthivel P; Gereke M; Breithaupt A; Fuchs D; Gigliotti L; Gruber AD; Dianzani U; Bruder D
PLoS One; 2014; 9(7):e100970. PubMed ID: 25029240
[TBL] [Abstract][Full Text] [Related]
15. Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy.
Fan X; Quezada SA; Sepulveda MA; Sharma P; Allison JP
J Exp Med; 2014 Apr; 211(4):715-25. PubMed ID: 24687957
[TBL] [Abstract][Full Text] [Related]
16. Survivin blockade sensitizes rhabdomyosarcoma cells for lysis by fetal acetylcholine receptor-redirected T cells.
Simon-Keller K; Paschen A; Hombach AA; Ströbel P; Coindre JM; Eichmüller SB; Vincent A; Gattenlöhner S; Hoppe F; Leuschner I; Stegmaier S; Koscielniak E; Leverkus M; Altieri DC; Abken H; Marx A
Am J Pathol; 2013 Jun; 182(6):2121-31. PubMed ID: 23562272
[TBL] [Abstract][Full Text] [Related]
17. The nature of activatory and tolerogenic dendritic cell-derived signal II.
Bakdash G; Sittig SP; van Dijk T; Figdor CG; de Vries IJ
Front Immunol; 2013; 4():53. PubMed ID: 23450201
[TBL] [Abstract][Full Text] [Related]
18. Advances in targeting cell surface signalling molecules for immune modulation.
Yao S; Zhu Y; Chen L
Nat Rev Drug Discov; 2013 Feb; 12(2):130-46. PubMed ID: 23370250
[TBL] [Abstract][Full Text] [Related]
19. The role of B7 family molecules in hematologic malignancy.
Greaves P; Gribben JG
Blood; 2013 Jan; 121(5):734-44. PubMed ID: 23223433
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
